Cardiology Plus最新文献

{"title":"Baseline platelet count independently predicts long-term adverse outcomes in patients undergoing percutaneous coronary intervention: a single-center retrospective cohort study","authors":"Xiangeng Hou, Ying-Ying Zheng, Tingting Wu, You Chen, Yi Yang, Yi-tong Ma, Xiang Xie","doi":"10.1097/CP9.0000000000000023","DOIUrl":"https://doi.org/10.1097/CP9.0000000000000023","url":null,"abstract":"Background and purpose: The association between platelet counts (PC) with clinical outcomes after percutaneous coronary intervention (PCI) in patients with coronary artery disease (CAD) has been reported by some but not all previous studies. The present study aims to investigate the association of PC with the outcomes of CAD patients who underwent PCI. Methods: We conducted a retrospective cohort study to examine the potential impact of baseline PC with long-term outcomes in patients receiving at least one stent. The final analysis included a total of 6,046 patients. The median follow-up was 32 (1–120) months Results: All-cause mortality did not differ significantly among the four groups based on baseline PC (lowest 25%, Quartile 1 [Q1], PC < 173, n = 1,473; 25%–50%, Quartile 2 [Q2], 173 ≤ PC < 208, n = 1,529; 50%–75%, Quartile 3 [Q3], 208 ≤ PC < 250, n = 1,507; and 75%–100%, Quartile 4 [Q4], PC ≥ 250, n = 1,537). The rate of major adverse cardiovascular and cerebrovascular events was 12.8% (188/1,473) in the Q1 group, 12.8% (196/1,529) in the Q2 group, 15.1% (228/1,507) in the Q3 group, and 16.3% (150/1,537) in the Q4 group (P = 0.010). The rate of major adverse cardiovascular events was 11.3% (167/1,473) in the Q1 group, 11.6% (177/1,529) in the Q2 group, 13.9% (210/1,507) in the Q3 group, and 15.0% (231/1,537) in the Q4 group (P = 0.004). Using Q1 as reference, the adjusted hazard ratio (aHR) for major adverse cardiovascular and cerebrovascular events in multivariate Cox regression was 1.212 (95% confidence interval [CI]: 1.004–1.455, P < 0.001) in Q2, 1.455 (95% CI: 1.200–1.766, P < 0.001) in Q3, and 1.754 (95% CI: 1.426–2.118, P < 0.001) in Q4. Using Q1 as reference, the aHR for major adverse cardiovascular events was 1.201(95% CI: 0.968–1.492, P = 0.096) in Q2, 1.489 (95% CI: 1.206–1.837, P < 0.001) in Q3, and 1.847 (95% CI: 1.500–2.275, P < 0.001) in Q4. Conclusion: A higher baseline PC was independently associated with an increased risk of major adverse cardiovascular and cerebrovascular events and major adverse cardiovascular events, but not all-cause-mortality in CAD patients after PCI.","PeriodicalId":52908,"journal":{"name":"Cardiology Plus","volume":"7 1","pages":"138 - 143"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61654755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mortality trend of heart diseases in China, 2013–2020","authors":"Z. Long, Yangyang Xu, Wei Liu, Lijun Wang, Maigeng Zhou, P. Yin, Y. Huo","doi":"10.1097/CP9.0000000000000019","DOIUrl":"https://doi.org/10.1097/CP9.0000000000000019","url":null,"abstract":"Background and purpose: Heart diseases are the leading cause of death in China. Understanding of the secular trend of different subcategories of heart disease is important for policy making. The purpose of this study is to analyze the mortality trend of heart diseases in China from 2013 to 2020. Methods: A population-based longitudinal analysis was conducted using the China National Mortality Surveillance System to examine heart disease mortality change during a period from 2013 to 2020. The causes of death were coded using the International Classification of Diseases-10th Revision. The number of deaths and mortality rate were calculated based on sex, subcategories of heart disease, urban versus rural setting, and across different geographic locations. Data from the sixth census in China in 2010 was used as the standard population, and the mortality rates were adjusted based on the under-reporting rate. Results: Ischemic heart disease (IHD), hypertensive heart disease (HHD), and rheumatic heart disease (RHD) are the three leading causes of heart disease deaths during 2013–2020. There was a trend for increased age-standardized mortality rate (ASMR) of cardiac arrest, aortic aneurysm (AA), and nonrheumatic valvular heart diseases (NRVHDs) during the study period. In comparison to men, women had higher ASMR of RHD, and lower ASMR of IHD, HHD, cardiac arrest, AA, and NRVHDs. In comparison to rural areas, urban areas had lower ASMR of IHD, HHD, and RHD, and higher ASMR of cardiac arrest, AA, and NRVHDs. The spectrum of heart diseases differed significantly across age groups. In 2020, the percentages of IHD and HHD in the ≥65-year age group were higher than in other age groups. Significant differences in ASMR were noted across different geographic locations, with the highest in Xinjiang (198.14/100,000) and the lowest in Shanghai (62.19/100,000) in 2020. Conclusions: The mortality rate decreased for IHD, HHD, and RHD during the study period, but remained the leading causes of heart disease death in China. There was a trend for increasing mortality of cardiac arrest, AA, and NRVHDs, and significant difference across different geographic locations.","PeriodicalId":52908,"journal":{"name":"Cardiology Plus","volume":"7 1","pages":"111 - 117"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47043933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor: C-reactive protein and cardiovascular events in obstructive and nonobstructive coronary artery disease","authors":"P. Sookaromdee, V. Wiwanitkit","doi":"10.1097/cp9.0000000000000010","DOIUrl":"https://doi.org/10.1097/cp9.0000000000000010","url":null,"abstract":"","PeriodicalId":52908,"journal":{"name":"Cardiology Plus","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49489727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Letter to the Editor: C-reactive protein and cardiovascular events in obstructive and nonobstructive coronary artery disease","authors":"Jian‐Jun Li","doi":"10.1097/cp9.0000000000000014","DOIUrl":"https://doi.org/10.1097/cp9.0000000000000014","url":null,"abstract":"","PeriodicalId":52908,"journal":{"name":"Cardiology Plus","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44436834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ALDH2 mutation results in excessive basal nitric oxide production and a delayed response to nitroglycerin","authors":"Hongming Zhu, Jingjing Hu, Z. Dong, Yang Liu, Xiaolei Sun, A. Sun","doi":"10.1097/CP9.0000000000000011","DOIUrl":"https://doi.org/10.1097/CP9.0000000000000011","url":null,"abstract":"Abstract Background and purpose: Nitroglycerin tolerance is a common phenomenon in patients with coronary artery disease (CAD). Aldehyde dehydrogenase 2 (ALDH2) is the enzyme that metabolizes nitroglycerin to its active form nitric oxide (NO). Previous studies showed altered nitroglycerin in subjects with ALDH2 mutation, but the functional impact on endothelial cells is not fully understood. Methods: In the first step of in vitro experiments, we examined functional properties of induced pluripotent stem cell-derived CD144+ endothelial cells (iPSC-ECs) that expressed wildtype (WT) vs ALDH2+/− variant. In the second step of human studies, diameter of the left anterior descending (LAD) coronary artery was determined using angiography in 151 adult volunteers (111 with WT ALDH2, 32 with ALDH2+/− and 8 with ALDH2−/− genotype) prior to as well as after intracoronary injection of 200-μg nitroglycerin. Results: Briefly, the ALDH2+/− iPSC-ECs demonstrated impaired low-density lipoprotein (LDL) uptake, proliferation, migration, tube formation, oxidative stress resistance, and viability. In comparison to the WT control, the ALDH2+/− iPSC-ECs had elevated NO production under baseline conditions, but exhibited a delayed NO release after nitroglycerin treatment. Exposure to 10-μg/mL nitroglycerin for 2 h increased NO production in WT iPSC-ECs but 4-h exposure was required to stimulate NO production in the ALDH2+/− iPSC-ECs. In comparison to the WT control, the subjects carrying the ALDH2+/− variants had seemingly larger LAD coronary artery diameter (3.5 and 3.8 mm vs 3.4 mm in the WT control), but attenuated vasodilatory response to nitroglycerin (ALDH2MUT group vs the WT control, 7.1 ± 0.6% vs 10.1 ± 0.8%, P = 0.024). Conclusion: These findings indicated elevated NO production by endothelia cells under basal conditions but attenuated response to nitroglycerin upon ALDH2 mutation.","PeriodicalId":52908,"journal":{"name":"Cardiology Plus","volume":"7 1","pages":"85 - 91"},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47000085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-dose aspirin for the prevention of atherothrombosis across the cardiovascular risk continuum","authors":"Jaqui Walker","doi":"10.1097/cp9.0000000000000017","DOIUrl":"https://doi.org/10.1097/cp9.0000000000000017","url":null,"abstract":"Professor Junbo Ge welcomed speakers and attendees both present (25, 600) and virtual (120,000) to the International Aspirin Foundation (IAF) Symposium at the Oriental Congress of Cardiology (OCC). He introduced aspirin as the cornerstone of antiplatelet therapy with evidence for its efficacy and safety in cardiovascular disease (CVD) prevention accumulating since the 1970s. Aspirin works by irreversibly inactivating the cyclooxygenase (COX) activity of the ubiquitous bifunctional enzyme, prostaglandin (PG)G/H-synthase, which catalyzes the conversion of arachidonic acid to PGG 2 (through its COX activity) and PGH 2 (through its peroxidase activity) 1 . PGH 2 is a common intermediate in the biosynthesis of different prostanoids (e.g., PGE 2 , thromboxane [TX] A 2 and prostacyclin [PGI 2 ]), through the action of tissue-specific isomerases and synthases. three clinical case studies to illustrate his perspectives on aspirin’s role in the prevention of cardiovascular events using data from both primary and secondary prevention trials. For secondary prevention of CVD, in those with known atherosclerotic disease prior myocardial infarction the that risk of in serious thrombotic atrial clear benefits for low-dose aspirin. Two of Professor Gaziano’s case studies illustrated the types of people benefiting from aspirin for the secondary prevention of CVD. There are over 13.7 million new strokes worldwide each year, with individuals having a lifetime risk of 20%. TIA and minor stroke comprise 70% of all acute cerebrovascular events and often herald an impending major stroke, with seven-day risk of major stroke as high as 10% 1,2 . However, urgent medical assessment and treatment are very effective in preventing early recurrent major stroke. The EXPRESS study showed urgent investigation/treatment after TIA and minor stroke reduced the 90-day risk of major recurrent stroke by about 80% - one of the most effective interventions in medicine 3,4 . This benefit was achieved by changing care from non-urgent general practice prescribing to urgent assessment and treatment using existing medications. Other studies show similar feasibility and results 5 . However, the EXPRESS Study intervention was multifactorial, including aspirin, other antiplatelet drugs in high-risk patients, BP-lowering drugs and statins, and it was uncertain which component had reduced stroke risk. Aspirin was given to all patients, but the effect of aspirin on recurrent stroke risk had long been considered modest, based on trials in acute major stroke and in long-term prevention after TIA/minor stroke. By detailed re-analysis of individual patient data from these trials, it was shown the acute benefits of aspirin in TIA/minor stroke had been considerably underestimated, showing that aspirin alone reduced 90-day risk of disabling recurrent stroke by 80% and of all stroke by 60% 6 . Despite patients given benefits of aspirin. this, Professor Rothwell has with guideline writers recommend low-dose ","PeriodicalId":52908,"journal":{"name":"Cardiology Plus","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42428058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Duchenne muscular dystrophy and dilated cardiomyopathy with deletion of exon 45 and 49","authors":"X. Zhuang, S. Luo, Huizhi Fan, Jin-Jin Zhang, Hua Chen, Ping-ping Yan, Liwen Bao","doi":"10.1097/CP9.0000000000000006","DOIUrl":"https://doi.org/10.1097/CP9.0000000000000006","url":null,"abstract":"Abstract A 26-year-old young man presented with paroxysmal chest pain and systemic edema that started 2 years earlier and worsened during the past 2 months. Echocardiogram indicated total heart enlargement as well as severe left and right ventricular systolic dysfunction. MRI revealed atrophy of most muscles in the thigh and calf on both sides. EMG suggested myogenic damage to myoelectrical changes and early recruitment changes. A diagnosis of Duchenne muscular dystrophy (DMD) was established on biopsy and genetic testing showing deletion of exons 45 and 49 of the dystrophin gene. He had no family history of major cardiovascular diseases. The patient disclosed later that muscle weakening started at 7 years of age. Symptoms improved after treatment with a variety of agents to manage heart failure and complications, and was discharged. He survived for 2 years, during which the general condition and heart failure deteriorated progressively. In summary, skeletal muscle weakness is typically the first sign of DMD, but heart involvement is commonly seen later. With the current treatment options, prognosis is poor. Gene therapy might be warranted.","PeriodicalId":52908,"journal":{"name":"Cardiology Plus","volume":"7 1","pages":"97 - 101"},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43784092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of hybutimibe on primary hypercholesterolemia: a randomized, double-blinded, placebo and positive–controlled, parallel phase II study","authors":"L. Qi, Shu-Lian Zhao, Jiyan Chen, Mei Zhang, Xiaodong Li, Yugang Dong, Xiaomei Guo, Kaikai Huang, Fang Wang, Y. Huo, J. Ge","doi":"10.1097/CP9.0000000000000012","DOIUrl":"https://doi.org/10.1097/CP9.0000000000000012","url":null,"abstract":"Abstract Background and purpose: Hybutimibe is proved to be safe in healthy adults by a phase I study. A multi-center, randomized, double-blind phase II clinical trial evaluated its effectiveness and safety of Hybutimibe in the treatment of primary hypercholesterolemia. Methods: A total of 244 patients between August 2014 and August 2015, with primary hypercholesterolemia from 15 centers in China were enrolled and randomly assigned to receive placebo, ezetimibe, or hybutimibe 5, 10, or 20 mg/day in a 1:1:1:1:1 ratio. The primary outcome was evaluated from the change rate of low-density lipoprotein cholesterol (LDL-C) at week 8 from baseline, whereas secondary outcomes were evaluated from the change rates of LDL-C, TC, TG, HDL-C, non-HDL-C, APO-B, APO-A1 at weeks 1, 2, 4, and 8 from baseline. Results: After 8 weeks of treatment, the average decrease rate of LDL-C was −20.01% for ezetimibe, −10.84% (95% CI: −14.67, −7.00) for hybutimibe 5 mg/day, −17.06% (95% CI: −20.83, −13.29) for hybutimibe 10 mg/day, and −17.04% (95% CI: −20.30, −13.79) for hybutimibe 20 mg/day, respectively. The change rates of TC, non-HDL-C, and APO-B levels were significantly improved in all treatments compared with placebo (P < 0.05), whereas changes in the above lipid profiles of hybutimibe 20 mg/day were similar with ezetimibe. In terms of safety, the most common adverse events were elevation in ALT, gastrointestinal reaction, dizziness, and headache. Conclusions: This clinical study found that hybutimibe with the least dose of 5 mg/day effectively improved the LDL-C, TC, non-HDL-C, and APO-B levels in patients with primary hyperlipidemia with good tolerance and safety with no significant effect on TG levels.","PeriodicalId":52908,"journal":{"name":"Cardiology Plus","volume":"7 1","pages":"77 - 84"},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41895719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Familial hypercholesterolemia in China requires greater efforts","authors":"Jianjun Li","doi":"10.1097/CP9.0000000000000013","DOIUrl":"https://doi.org/10.1097/CP9.0000000000000013","url":null,"abstract":"Familial hypercholesterolemia (FH) is one of the most common genetic disorders characterized by a predominant elevation in plasma low-density lipoprotein (LDL) cholesterol (LDL-C) concentration and higher incidence of premature atherosclerotic cardiovascular disease (ASCVD). It has been reported that the long-term coronary artery disease (CAD) and ASCVD risk in the US adults with the FH phenotype are up to approximately five-fold higher than that in the general population.[1] It has also been estimated that there is an important longterm burden of ASCVD in phenotypic but undiagnosed FH patients in the US, with the acceleration of CAD risk by 20–30years.[1] In recent years, the features of underdiagnosis and under-treatment of FH patients has attained an intensive attention worldwide.[2] This increased risk is age dependent, with the highest relative risk in younger index ages. Notably, several atherosclerosisrelated international academic organizations or societies have issued statements or guidelines consequently, which call for the actions to improve the diagnosis and treatment of this unique, treatable disease globally.[3–6] In the Asia Pacific region, FH is estimated to affect at least 15 million people.[7] Among them, China alone may account for more than half of the FH patients as it is the world’s most populous country. The general knowledge regarding FH is not very unfamiliar for medical professionals. Premature ASCVD is a great concern in FH patients due to the extremely high plasma LDL-C concentration. If homozygous FH (HoFH) is left untreated, tendon xanthomas may usually be detected.[2] Since the 1950s, FH patients have been divided into heterozygous FH (HeFH) and HoFH, and diagnosing HeFH and HoFH based on the phenotypic features of ASCVD or xanthomas has frequently been difficult without the DNA analysis of FH genes.[3] With the development of genetic testing technology, multiple studies revealed that a severe defect in the ability to bind and internalize LDL particles was caused by mutations in both alleles of the","PeriodicalId":52908,"journal":{"name":"Cardiology Plus","volume":"7 1","pages":"61 - 63"},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44149927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is Omega-3 Index necessary for fish oil supplements for CVD risk prevention?","authors":"Chen Luo, Zhenyue Chen","doi":"10.1097/CP9.0000000000000015","DOIUrl":"https://doi.org/10.1097/CP9.0000000000000015","url":null,"abstract":"Abstract Several large prospective cohort studies demonstrated an association between higher cardiovascular disease (CVD) risk with low blood level of omega-3 fatty acids as well as low Omega-3 Index [<4% eicosapentaenoic acid (EPA)+ docosahexaenoic acid (DHA) to total fatty acids in red blood cell membrane]. However, randomized controlled trials of omega-3 fatty acids as either primary or secondary prevention have yielded controversial results. In this review, we summarize the evidence that supports or argues against the use omega-3 fatty acids, with a focus on the underlying mechanisms for the observed discrepancies (eg, differences in dosage, comparators and EPA levels or Omega-3 Index). Omega-3 Index is an independent risk factor for cardiovascular risk. The baseline Omega-3 Index can be used as a reference for whether and how much fish oil should be supplemented. To some degree, it can be used to explain why there are so much inconsistencies in clinical trials. Omega-3 Index could be a promising treatment target in clinical practice and in public health settings although there are still some barriers. This review summarizes current evidences from both epidemiological studies and randomized controlled trials of omega-3 fatty acids as primary and secondary prevention of CVD, and aims to provide a comprehensive overview of fish oil supplements on risk for CVD, and Omega-3 Index as a tool to identify subjects at high risk as well as a treatment target in CVD prevention.","PeriodicalId":52908,"journal":{"name":"Cardiology Plus","volume":"7 1","pages":"70 - 76"},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46445527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}